Your browser doesn't support javascript.
loading
Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals.
Lacaze, Paul; Sebra, Robert; Riaz, Moeen; Tiller, Jane; Revote, Jerico; Phung, James; Parker, Emily J; Orchard, Suzanne G; Lockery, Jessica E; Wolfe, Rory; Strahl, Maya; Wang, Ying C; Chen, Rong; Sisco, Daniel; Arnold, Todd; Thompson, Bryony A; Buchanan, Daniel D; Macrae, Finlay A; James, Paul A; Abhayaratna, Walter P; Lockett, Trevor J; Gibbs, Peter; Tonkin, Andrew M; Nelson, Mark R; Reid, Christopher M; Woods, Robyn L; Murray, Anne M; Winship, Ingrid; McNeil, John J; Schadt, Eric.
Afiliação
  • Lacaze P; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. paul.lacaze@monash.edu.
  • Sebra R; Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Riaz M; Sema4, Stamford, CT, USA.
  • Tiller J; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Revote J; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Phung J; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Parker EJ; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Orchard SG; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Lockery JE; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Wolfe R; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Strahl M; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Wang YC; Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Chen R; Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sisco D; Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Arnold T; Sema4, Stamford, CT, USA.
  • Thompson BA; Sema4, Stamford, CT, USA.
  • Buchanan DD; Sema4, Stamford, CT, USA.
  • Macrae FA; Department of Genomic Medicine; Family Cancer Clinic, Department of Medicine, Department of Pathology, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
  • James PA; Department of Genomic Medicine; Family Cancer Clinic, Department of Medicine, Department of Pathology, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
  • Abhayaratna WP; Colorectal Oncogenomics Group, Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
  • Lockett TJ; Department of Genomic Medicine; Family Cancer Clinic, Department of Medicine, Department of Pathology, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
  • Gibbs P; Department of Genomic Medicine; Family Cancer Clinic, Department of Medicine, Department of Pathology, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
  • Tonkin AM; College of Health and Medicine, The Australian National University, Canberra, Australia.
  • Nelson MR; CSIRO Health and Biosecurity, North Ryde, NSW, Australia.
  • Reid CM; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Woods RL; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Murray AM; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Winship I; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
  • McNeil JJ; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Schadt E; School of Public Health, Curtin University, Perth, WA, Australia.
Genet Med ; 22(11): 1883-1886, 2020 11.
Article em En | MEDLINE | ID: mdl-32606442
ABSTRACT

PURPOSE:

To measure the prevalence of medically actionable pathogenic variants (PVs) among a population of healthy elderly individuals.

METHODS:

We used targeted sequencing to detect pathogenic or likely pathogenic variants in 55 genes associated with autosomal dominant medically actionable conditions, among a population of 13,131 individuals aged 70 or older (mean age 75 years) enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Participants had no previous diagnosis or current symptoms of cardiovascular disease, physical disability or dementia, and no current diagnosis of life-threatening cancer. Variant curation followed American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) standards.

RESULTS:

One in 75 (1.3%) healthy elderly individuals carried a PV. This was lower than rates reported from population-based studies, which have ranged from 1.8% to 3.4%. We detected 20 PV carriers for Lynch syndrome (MSH6/MLH1/MSH2/PMS2) and 13 for familial hypercholesterolemia (LDLR/APOB/PCSK9). Among 7056 female participants, we detected 15 BRCA1/BRCA2 PV carriers (1 in 470 females). We detected 86 carriers of PVs in lower-penetrance genes associated with inherited cardiac disorders.

CONCLUSION:

Medically actionable PVs are carried in a healthy elderly population. Our findings raise questions about the actionability of lower-penetrance genes, especially when PVs are detected in the absence of symptoms and/or family history of disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Hereditárias sem Polipose / Pró-Proteína Convertase 9 Tipo de estudo: Guideline / Risk_factors_studies Limite: Aged / Female / Humans Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Hereditárias sem Polipose / Pró-Proteína Convertase 9 Tipo de estudo: Guideline / Risk_factors_studies Limite: Aged / Female / Humans Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália